Faeth Therapeutics adds Karen Vousden to board, expanding it to six directors
Faeth Therapeutics appointed Karen Vousden, Ph.D., a cancer biologist and company co-founder, as a Class II director effective immediately, after increasing the board from five to six seats. She also joined the Compensation Committee, and will receive a 25,000-share stock option under the company's director compensation program.
Key points
- Board expanded from five to six directors on September 11, 2026.
- Dr. Vousden's term runs until the 2029 annual meeting of stockholders.
- Initial grant is an option to purchase 25,000 shares of common stock, vesting monthly through the third anniversary of the grant date.
- Dr. Vousden is a Principal Group Leader at The Francis Crick Institute and a director of Bristol Myers Squibb Company since 2018.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.